Question 1

What is Corvus Pharmaceuticals, Inc.'s WACC?

Accepted Answer

Corvus Pharmaceuticals, Inc. (CRVS) has a Weighted Average Cost of Capital (WACC) of 8.71%. This is calculated using a Cost of Equity of 8.71% (via CAPM with a beta of 1.00) and a pre-tax Cost of Debt of 5.00%, with an equity weight of 100.00% in the capital structure.

Question 2

Is Corvus Pharmaceuticals, Inc.'s WACC high or low?

Accepted Answer

Corvus Pharmaceuticals, Inc.'s WACC of 8.71% falls within the typical 8-12% range for mid-cap growth companies. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Question 3

How is Corvus Pharmaceuticals, Inc.'s WACC calculated?

Accepted Answer

Corvus Pharmaceuticals, Inc.'s WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 8.71% is derived from the CAPM model using a beta of 1.00. The pre-tax Cost of Debt (Rd) is 5.00%. The capital structure is 100.00% equity and 0.00% debt.

Corvus Pharmaceuticals, Inc. (CRVS) — WACC 分析

WACC 构成

解读

Corvus Pharmaceuticals, Inc.（CRVS）WACC：8.71%

WACC计算器

Corvus Pharmaceuticals, Inc.（CRVS） WACC 解读

CRVS 公司分析

CRVS DCF 估值

继续做同行对比